Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)

INCLUSION CRITERIA : * Male older than 18 years-old, * Squamous cell carcinoma of the penis of clinical stages N3 and/or M1, * Central Histological confirmation of diagnosis of wild-type K-ras penis cancer (histological documentation of the mutational status prior to each patient's registration). Nota Bene: an archival tumor sample must be available. * At least one measurable lesion according to the RECIST version 1.1. In case of relapsing patient, documented progression as per RECIST version 1.1, * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2, * Life expectancy ≥ 6 months, * Adequate organs functions defined as the following (transfusion is not allowed within 7 days prior to lab test performed to assess the eligibility): * Hemoglobin ≥ 9 mg/dL, * Absolute Neutrophils Count ≥ 1,5 Gi/l, * Platelets ≥ 100 Gi/l, * Creatinine ≤ 1,5 x Upper Limit of Normal (ULN) and Creatinine clearance ≥ 60 ml/min (calculated with Cockcroft formula or Modification of Diet in Renal Disease (MDRD) formula for patients older than 65 years old) * Aspartate aminotransferase (ASAT) and Alanine aminotransferase (ALAT) ≤ 2,5 x ULN (≤ 5 x ULN in presence of liver metastasis) * Total bilirubin ≤ 1,5 x ULN, * Willingness to use effective contraceptive method during the whole treatment period and up to 4 months after the last study drug administration, * Affiliated to the French social security system, * Subjects must provide written informed consent prior to perform any s…